Company intelligence / Profile preview
ZielBio
Charlottesville, Virginia, United Stateszielbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ZielBio’s lead asset ZB131—a proprietary monoclonal antibody targeting CSP—has received FDA Orphan Drug Designation for both pancreatic cancer and cholangiocarcinoma. A Phase 1/2 clinical trial of ZB131 in advanced solid tumors including pancreatic cancer is actively enrolling patients as of late 2022. The company leverages its Zielfind™ technology to identify new druggable targets with a focus on oncology.[4][5][6]
- Therapeutic areas
- OtherOncology
- Modalities
- monoclonal antibodies (mAbs)therapeutic interventions (general)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on ZielBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZielBio.